ALT 5计划分拆为两家独立上市公司

2024-10-02 21:00

ALT5 Sigma (NASDAQ:ALTS) on Wednesday reported a strategic plan to separate into two distinct companies, sending shares down in premarket trade.
Following consummation of this plan, ALT5 will execute the separation of its Fintech and Biotech businesses, with ALT5 continuing as a fintech organization post-separation.
The Biotech segment will emerge as Alyea Therapeutics Corporation, an independent firm dedicated to developing non-addictive pain management therapies.
As standalone entities, both companies are expected to benefit from: increased focus and agility within their respective industries, tailored capital allocation strategies to pursue differentiated strategic growth objectives.
The plan has been unanimously approved by the company's board, following an evaluation of alternatives that have been underway since the acquisition of fintech innovator ALT5 Sigma (subsidiary) in May of this year, ALT5 Sigma (ALTS) said.
Both ALT5 Pay and ALT5 Prime are experiencing increased customer engagement, with transaction volumes now exceeding $2 billion on an annualized basis.
ALTS -2.73% premarket to $1.78.
Source: Press Release

More on ALT5 Sigma